Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Study source : Www.sutrobio.com save search
BioNova Announces First Patient Dosed in a Phase 1/2 Study of BN301 for the Treatment of Hematologic Malignancies in China
Published: 2023-02-13 (Crawled : 17:00) - sutrobio.com
STRO M | $3.8 -3.55% -4.23% 720K
|
Health Technology
|
| O: -0.31%
H: 8.62%
C: -1.88%
bn301 treatment china study phase 1
Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer
Published: 2023-01-09 (Crawled : 22:00) - sutrobio.com
PCVX | $62.43 0.31% 0.34% 31
|
Health Technology
|
| O: -0.3%
H: 1.79%
C: 0.35%
STRO M | $3.8 -3.55% -4.23% 720K
|
Health Technology
|
| O: 1.93%
H: 0.89%
C: -14.08%
stro-002 biopharma update cancer study ovarian cancer phase 1
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
INVO | $1.82 139.47% 49.67% 1.4M
|
Health Technology
HOLO | $2.24 -5.49% 27.74% 7.7M
|
SRFM 4 | $0.3859 -12.3% 23.84% 660K
|
n/a
CTM | $0.2201 -2.31% 22.67% 48K
|
n/a
VIAO | $0.262 0.77% 16.03% 14M
|
Electronic Technology
DXF | $0.2708 -5.71% 14.48% 190K
|
Finance
GRFX | $0.2159 -10.04% 12.55% 5.9K
|
n/a
BHIL | $0.1722 -3.8% 12.08% 290K
|
Agriculture, Forestry, Fishing ...
MCW 4 | $6.49 -1.22% 10.94% 6
|
Professional, Scientific, and T...
ANVS | $8.99 -10.81% 10.9% 270K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.